APA (7th ed.) Citation

Burge, M., Goldstein, D., Haydon, A., Pavlakis, N., Lemech, C., Hammond, E., . . . Chojnowski, G. M. Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Burge, Matthew, et al. Phase Ib Open-label, Multicenter Study of Pixatimod, an Activator of TLR9, in Combination with Nivolumab in Subjects with Microsatellite-stable Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma and Other Solid Tumors. BMJ Publishing Group.

MLA (9th ed.) Citation

Burge, Matthew, et al. Phase Ib Open-label, Multicenter Study of Pixatimod, an Activator of TLR9, in Combination with Nivolumab in Subjects with Microsatellite-stable Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma and Other Solid Tumors. BMJ Publishing Group.